
Phytochemicals as Lead Compounds for New Drug Discovery
- 1st Edition - September 7, 2019
- Imprint: Elsevier
- Editors: Chukwuebuka Egbuna, Shashank Kumar, Jonathan C. Ifemeje, Shahira M. Ezzat, Saravanan Kaliyaperumal
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 9 0 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 9 1 - 1
Phytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quotePhytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the development of new drugs and chemical entities. Functional bioactive compounds of plant origin have been an invaluable source for many human therapeutic drugs and have played a major role in the treatment of diseases around the world. These compounds possess enormous structural and chemical diversity and have led to many important discoveries. This book presents fundament concepts and factors affecting the choice for plant-based products, as well as recent advances in computer-aided drug discovery and FDA drug candidacy acceptance criteria. It also details the various bioactive lead compounds and molecular targets for a range of life-threatening diseases including cancer, diabetes, and neurodegenerative diseases.
Written by a global team of experts, Phytochemicals as Lead Compounds for New Drug Discovery is an ideal resource for drug developers, phytochemists, plant biochemists, food and medicinal chemists, nutritionists and toxicologists, chemical ecologists, taxonomists, analytical chemists, and other researchers in those fields. It will also be very valuable to professors, students, and researchers in this domain.
- Presents fundamental concepts and factors affecting choice for plant-based products
- Details the FDA drug candidacy acceptance criteria, including bottlenecks and way forward
- Highlights recent advances in computational-based drug discovery
- Focuses on the discovery of new drugs and potential druggable targets for the treatment of chronic diseases of world importance
Researchers working in drug development, phytochemists, plant biochemists, food and medicinal chemists, nutritionists, toxicologists, chemical ecologists, taxonomists, and analytical chemists
- Edition: 1
- Published: September 7, 2019
- No. of pages (Paperback): 378
- Imprint: Elsevier
- Language: English
- Paperback ISBN: 9780128178904
- eBook ISBN: 9780128178911
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
SK
Shashank Kumar
JI
Jonathan C. Ifemeje
SE
Shahira M. Ezzat
SK